Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Myriad Genetics (MYGN) Long-Term Deferred Tax (2016)

Myriad Genetics (MYGN) has disclosed Long-Term Deferred Tax for 6 consecutive years, with $13.5 million as the latest value for Q4 2015.

  • On a quarterly basis, Long-Term Deferred Tax changed N/A to $13.5 million in Q4 2015 year-over-year; TTM through Dec 2015 was $13.5 million, a N/A change, with the full-year FY2014 number at $3.2 million, down 88.89% from a year prior.
  • Long-Term Deferred Tax was $13.5 million for Q4 2015 at Myriad Genetics, up from $407000.0 in the prior quarter.
  • In the past five years, Long-Term Deferred Tax ranged from a high of $30.6 million in Q2 2012 to a low of $407000.0 in Q1 2015.
  • A 5-year average of $23.5 million and a median of $28.0 million in 2012 define the central range for Long-Term Deferred Tax.
  • Peak YoY movement for Long-Term Deferred Tax: soared 175.02% in 2011, then plummeted 88.89% in 2014.
  • Myriad Genetics' Long-Term Deferred Tax stood at $28.1 million in 2011, then dropped by 12.43% to $24.6 million in 2012, then rose by 21.93% to $30.0 million in 2013, then tumbled by 89.39% to $3.2 million in 2014, then skyrocketed by 324.53% to $13.5 million in 2015.
  • Per Business Quant, the three most recent readings for MYGN's Long-Term Deferred Tax are $13.5 million (Q4 2015), $407000.0 (Q1 2015), and $3.2 million (Q2 2014).